LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

Search

Geron Corp

Fermé

SecteurSoins de santé

1.48 -1.33

Résumé

Variation du prix de l'action

24h

Actuel

Min

1.48

Max

1.55

Chiffres clés

By Trading Economics

Revenu

5.5M

-20M

Ventes

-7.9M

40M

BPA

-0.03

Marge bénéficiaire

-50.085

Employés

229

EBITDA

-375K

-17M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+169.74% upside

Dividendes

By Dow Jones

Prochains Résultats

7 août 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-782M

904M

Ouverture précédente

2.81

Clôture précédente

1.48

Sentiment de l'Actualité

By Acuity

75%

25%

354 / 380 Classement par Healthcare

Geron Corp Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

26 juin 2025, 23:49 UTC

Résultats

Nike Sees Sales Decline Decelerating in 1Q as Turnaround Strategy Plays Out -- 2nd Update

26 juin 2025, 22:19 UTC

Acquisitions, Fusions, Rachats

FTC Clears Alimentation Couche-Tard's $1.57 Billion GetGo Acquisition

26 juin 2025, 21:30 UTC

Résultats

Nike 4Q Profit, Revenue Slides as Turnaround Strategy Plays Out -- Update

26 juin 2025, 21:07 UTC

Résultats

Nike 4Q Profit, Revenue Slide as Turnaround Strategy Plays Out

26 juin 2025, 23:49 UTC

Market Talk

Nikkei May Rise as Fears About Middle East Conflict Ebb -- Market Talk

26 juin 2025, 23:39 UTC

Market Talk

Gold Edges Lower, Weighed by Stronger-Than-Expected U.S. Data -- Market Talk

26 juin 2025, 23:34 UTC

Acquisitions, Fusions, Rachats

Wesfarmers: Lease Reset Provides Opportunity for Upgrades, Extensions

26 juin 2025, 23:33 UTC

Acquisitions, Fusions, Rachats

Wesfarmers: 62 BWP-Owned Bunnings Sites Get Significantly Longer Leases

26 juin 2025, 23:32 UTC

Acquisitions, Fusions, Rachats

Wesfarmers Will No Longer Receive Earnings From BWP Management

26 juin 2025, 23:32 UTC

Acquisitions, Fusions, Rachats

Wesfarmers to Increase BWP Holding to 23.5% From 22.3%

26 juin 2025, 23:31 UTC

Acquisitions, Fusions, Rachats

Wesfarmers: New BWP Units Priced at 9.2% Premium to Last Close

26 juin 2025, 23:31 UTC

Acquisitions, Fusions, Rachats

BWP to Pay A$100 Mln Cash, A$42.6 Mln in New Units

26 juin 2025, 23:30 UTC

Acquisitions, Fusions, Rachats

Wesfarmers' Bunnings, BWP Trust to Extend and Vary Leases

26 juin 2025, 23:29 UTC

Acquisitions, Fusions, Rachats

Wesfarmers to Sell BWP Management to BWP Trust for A$142.6M

26 juin 2025, 23:19 UTC

Acquisitions, Fusions, Rachats

Andlauer Healthcare Group: Ontario Superior Court of Justice Issues Final Order Approving Sale to UPS

26 juin 2025, 22:06 UTC

Résultats

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

26 juin 2025, 21:15 UTC

Résultats

Nike 4Q Profit, Rev Slides as Turnaround Strategy Plays Out -- Update

26 juin 2025, 21:07 UTC

Acquisitions, Fusions, Rachats

Couche-Tard: 35 Stores to Be Divested in Accordance With Regulatory Requirements >ATD.T

26 juin 2025, 21:07 UTC

Acquisitions, Fusions, Rachats

Couche-Tard: GetGo Will Operate as Separate, Stand-Alone Business Unit, Maintain myPerks Loyalty Program >ATD.T

26 juin 2025, 21:07 UTC

Acquisitions, Fusions, Rachats

Couche-Tard: Buyer Will be Approved by the FTC >ATD.T

26 juin 2025, 21:07 UTC

Résultats

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

26 juin 2025, 21:06 UTC

Acquisitions, Fusions, Rachats

Couche-Tard Agreed to Sell 35 Sites, Including 34 Circle K Locations and One GetGo Property >ATD.T

26 juin 2025, 21:06 UTC

Acquisitions, Fusions, Rachats

Couche-Tard: Transaction Is Expected to Close in the Coming Days >ATD.T

26 juin 2025, 21:06 UTC

Market Talk

Bank of Mexico Seen Likely to Slow Pace of Rate Cuts -- Market Talk

26 juin 2025, 21:05 UTC

Acquisitions, Fusions, Rachats

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

26 juin 2025, 21:05 UTC

Acquisitions, Fusions, Rachats

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

26 juin 2025, 20:52 UTC

Résultats

Nike 4Q Profit, Rev Slide as Turnaround Strategy Plays Out

26 juin 2025, 20:51 UTC

Résultats

Correct: Nike 4Q Net $211M, Not $200M >NKE

26 juin 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

26 juin 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

Comparaison

Variation de prix

Geron Corp prévision

Objectif de Prix

By TipRanks

169.74% hausse

Prévisions sur 12 Mois

Moyen 4.1 USD  169.74%

Haut 6 USD

Bas 1.5 USD

Basé sur 7 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

7 ratings

5

Achat

2

Maintien

0

Vente

Sentiment

By Acuity

354 / 380Classement par Soins de santé

Sentiment de l'Actualité

Très Fortes Indications Baissières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Geron Corp

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.